Trastuzumab
HERZUMA (trastuzumab) is a biosimilar medication used to treat certain breast cancers that are HER2-positive. It's administered intravenously as an injection in a 420 mg dose. Manufactured by Celltrion Inc., it's a HER2/neu receptor antagonist that helps block cancer cell growth. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | HERZUMA (trastuzumab) is a biosimilar medication used to treat certain breast cancers that are HER2-positive. It's administered intravenously as an injection in a 420 mg dose. Manufactured by Celltrion Inc., it's a HER2/neu receptor antagonist that helps block cancer cell growth. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Trastuzumab",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Trastuzumab — ANDA 761106 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761106"
}
]
|
| identifier | ANDA761106 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-manufacturers",
"health-care",
"medications",
"pharmaceuticals"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Trastuzumab |
